• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Biol . Evolution of a truncated nucleocapsid protein enhances SARS-CoV-2 fitness by suppressing antiviral responses

tetano

Editor, Senior Moderator
PLoS Biol


. 2026 Apr 1;24(4):e3003646.
doi: 10.1371/journal.pbio.3003646. eCollection 2026 Apr.
Evolution of a truncated nucleocapsid protein enhances SARS-CoV-2 fitness by suppressing antiviral responses

Rory P Mulloy[SUP] 1 [/SUP], Danyel Evseev[SUP] 1 [/SUP], Noga Sharlin[SUP] 1 [/SUP], Maxwell P Bui-Marinos[SUP] 1 [/SUP], Émile Lacasse[SUP] 2 [/SUP], Isabelle Dubuc[SUP] 2 [/SUP], Louis Flamand[SUP] 2 3 [/SUP], Jennifer A Corcoran[SUP] 1 [/SUP]


Affiliations
Abstract

Viruses face selective pressure to evade cellular antiviral responses to control the outcome of an infection. However, due to their limited genome size, viruses must adopt unique strategies to confront cellular sensors. Since its emergence in humans, SARS-CoV-2 accrued many mutations; however, the functional consequence of many such genetic changes remains unexplored. Here, we show that SARS-CoV-2 produces a truncated form of the nucleocapsid protein, called N*M210. Due to the acquisition of a viral transcription regulatory sequence (TRS) in the N gene, certain variants like Omicron produce a new viral mRNA that markedly increases N*M210 production. We show that N*M210 is a double-stranded RNA (dsRNA)-binding protein. Using its dsRNA binding motif, N*M210 inhibits multiple antiviral responses, supressing interferon, triggering processing body disassembly, and potently blocking G3BP1 foci, including stress granules and RNase L-dependent bodies. Using a panel of recombinant SARS-CoV-2 viruses (rSARS-2), we show that enhanced N*M210 production increases virus fitness in primary human cells and in mice. Furthermore, we show that during infection N*M210 improves virus fitness, in part, due to its ability to potently block G3BP1 foci. We propose a model where, to evade the cellular antiviral response, SARS-CoV-2 has evolved a mechanism to increase the production of a truncated form of the N protein, which limits activation of dsRNA-induced antiviral responses, tipping the balance in favor of the virus in the battle for control of the cell.


 
Back
Top